Table 2.
% Pain | ||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Study | Quality | Continent a | Setting b | Cancer c | Mean Age | Sample | None | Mild | Moderate | ModSev d | Severe | Overall |
Alt-Epping, 2016 [33] | 16 | 2 | 2 | 60.6 | 22 | 22.7 | 18.2 | 45.5 | 59.1 | 13.6 | 77.3 | |
Andersen, 2014 [34] | 16 | 2 | 2 | 5 | 133 | 60 | 7 | 37 | ||||
Bibby, 2019 [35] | 15 | 2 | 2 | 11 | 64 | 229 | 43.7 | |||||
Efficace, 2015 [36] | 16 | 1,2,3 | 2 | 10 | 70.02 | 280 | 45 | 43.2 | 11.8 | 55 | ||
Esser, 2017 [37] | 15 | 2 | 2 | 10 | 50.4 | 239 | 15 | |||||
Gjeilo, 2020 [38] | 18 | 2 | 1,2 | 4 | 65.8 | 264 | 60 | 40 | ||||
Godby–a, 2021 [39] Godby–b, 2021 [39] |
18 18 |
1 1 |
2 2 |
6 6 |
70 70 |
46 309 |
75.6 40.7 |
|||||
Hong, 2015 [40] | 15 | 3 | 1 | 6 | 62.18 | 165 | 62.4 | |||||
Kirchheiner, 2015 [41] | 17 | 2 | 2 | 9 | 50 | 6.0 | ||||||
Kuon, 2019 [42] | 17 | 2 | 2 | 4 | 63.6 | 208 | 34.6 | |||||
Lunde, 2019 [43] | 18 | 2 | 2 | 9 | 67.2 | 207 | 16.9 | |||||
Ravn Munkvold, 2018 [44] | 18 | 2 | 1 | 2 | 507 | 48 | 30 | 12 | 22 | 10 | 52 | |
Roy, 2016 [45] | 16 | 3 | 2 | 4 | 56.4 | 36 | 47.2 | |||||
Russo, 2018 [46] | 17 | 2 | 2 | 2 | 52.7 | 527 | 12.5 | |||||
Salwey, 2020 [47] | 19 | 2 | 2 | 60 | 26.7 | 20 | 53.3 | 73.3 | ||||
Tang, 2015 [48] | 18 | 6 | 1 | 11 | 55.1 | 91 | 46.8 | 21.1 | 63.2 | |||
Thomas, 2017 [49] | 15 | 1 | 2 | 1 | 66 | 105 | 63 | |||||
Wang, 2021 [50] | 16 | 3 | 2 | 5 | 50.99 | 88 | 4.5 | |||||
Williams, 2021 [51] | 15 | 1 | 2 | 6 | 70.1 | 364 | 45.1 | |||||
Yao, 2020 [52] | 15 | 1 | 2 | 7 | 83 | 69.2 | 23.1 | 5.8 | 7.7 | 1.9 | 30.8 |
a 1 = North America; 2 = Europe; 3 = Asia; 4 = South America; 5 = Africa; 6 = Australia/New Zealand; b 1 = inpatient; 2 = outpatient; 3 = patient in a palliative care setting; 4 = all; 5 = other; c 1 = >3 types of cancer; 2 = head and neck; 3 = oesophagus, 4 = bronchus/lung; 5 = breast; 6 = gastro-intestinal; 7 = prostate; 8 = other, urological; 9 = gynaecological; 10 = haematological; 11 = other; d moderate–severe pain.